

A PATIENT IDENTIFICATION – To be completed by the member.

C. P. 3950 Lévis (Québec) G6V 8C6 <u>desjardinslifeinsurance.com/planmember</u> 1-844-410-6485

PRIOR AUTHORIZATION REQUEST

SATIVEX (DELTA-9 TETRAHYDROCANNABINOL/C)

PLEASE READ THE INSTRUCTIONS ON THE LAST PAGE OF THIS FORM.

Patient's last and first name		Relationship with member			Patient's dat	Patient's date of birth	
		Member	Spouse	Dependent child			
Member's last and first na	nme		Contract No.	(Certificate No.		
No., street, apt. City			1	<u> </u>	Province	Postal code	
Telephone Nos – Home:	Extension: Email:						
Since the response to this	request includes confidential information, please indicate	how you would	l like to be informe	ed of the decision:			
\square By mail (The response	to your request will be sent to the address indicated in thi	s section.)	☐ By fax:				
	s: If the patient has coverage under a private insurance p a copy of the decision notice and this form filled out by t				n, please subm	it the request to this	
	Does the patient have drug coverage under a private	insurance plan?					
	Yes – Please provide a copy of the notice of approv	al or refusal.	$ ightarrow$ \Box Copy at	ttached to this form	1.		
PRIVATE PLAN	Specify: Name of the insurer:		Contract No.: _		_ Certificate No.	:	
	□ No						
	Has a request for reimbursement been submitted und	der your provinc	cial plan?				
PROVINCIAL PLAN	☐ Yes – Please provide a copy of the notice of approv	val or refusal.	→ Copy at	ttached to this forn	1.		
	No – Please explain:						
PATIENT SUPPORT PROGRAM	Is the patient enrolled in a patient support program?	Yes N	lo				
	If so – Program name:						
FROGRAM	Contact person:	Telephone No.:			E	Extension:	
DECLARATION AND A	UTHORIZATION FOR THE COLLECTION AND CON	MUNICATIO	N OF PERSONA	AL INFORMATIO	N		
Insurance, strictly for the the information deemed n and insurance companies; when necessary use the prof personal information co	e provided on the claim form is accurate and complete. purposes of managing my file and settling this claim to: (a necessary to manage my file. The non-exhaustive list of sou (b) communicate to the said persons or organizations only ersonal information it may have about me in existing files the procerning my dependents, insofar as applicable to the claim) collect from ar rces from which the personal inf nat are now clos	ny person or legal n information may formation about n ted. This authorizat of this authorizat	entity, or from any be collected include ne that is deemed no tion is also valid for	public or parapi es healthcare pro ecessary for the the collection, u	ublic organization, only ofessionals or facilities, purposes of my file; (c)	
Signature of member:				Date:			
Last name and first name	of parent/legal guardian (if applicable):						
Signature of patient or pa	Date:						
CONSENT TO THE CO	MMUNICATION OF PERSONAL INFORMATION TO	O A THIRD PA	RTY				
	claim more efficiently, do you authorize Desjardins Insura of the reasons for the decision on your prior authorization		the patient suppo	ort program and the	e attending phys	sician or the attending	
Signature of member:	,			Date:			
Ū				Date.			
	of parent/legal guardian (if applicable):						
Signature of patient or pa	Signature of patient or parent/legal guardian (if applicable): Date:						

CONTINUED ON THE BACK

	ATTENDING PHYSICIAN SECTION — To be completed by the attending physician.										
F	Physician's last and first name (PLEASE Pl	License No.		Specialty							
1	No., street, suite	City		'	Province	Postal code					
1	Telephone No.:				'						
	Signature of physician: Date:										
_	Drug name		Formulation S	trength	Dosage	Patient's weight	Scheduled dura	ation of treatment			
\	Where is the drug administered?	Home Phys		rivate clinic	☐ Hospital – Inp	atient Hos	pital – Outpatien	t			
	 Make sure to fill out all sections so we can process the request faster. If any information is missing, we will send the form back to the member. In order to consider any diagnosis not mentioned on this form, we need supporting documents (clinical practice guidelines, clinical studies, etc.) that justify the drug's use in the given context. 										
ı	Diagnosis										
[Refractory neuropathic pain										
_	Refractory pain in patient with advance	ced cancer									
[\square Refractory spasticity associated with r	multiple sclerosis or s	spinal cord injury								
[\square Other therapeutic indication(s) – Plea	se specify:									
ſ	PRIOR MEDICATION OR TREATMENT										
ŀ	Has the patient ever used medication or	received treatment f	for this medical condition	on? ∐Yes	□No						
I	f not, please explain:										
I	f so, please list any medication already ι	ised or any treatmen	t already received for t	his medical co	ondition:						
	MEDICATION OR TREATMENT NAME		ОИТСОМЕ				TREATMEN				
	Name:		Inefficiency	Intoler	rance Contra	indication	From:	YYYY MM DD			
	Dose:		Specify:				То:	YYYY MM DD			
-	Name:		Inefficiency	Intoler	rance Contra	indication	From:	YYYY MM DD			
								1000/ 1414 DD			
-	Dose:		Specify:				To:	YYYY MM DD			
_				Intoler	rance Contra	indication	To: From:	YYYY MM DD			
_	Dose:		Specify:	Intoler	rance Contra	indication	To: From:				
-	Dose:		Specify:	Intoler		indication	To: From: To: From:	YYYY MM DD YYYY MM DD			
-	Dose: Name: Dose:		Specify: Inefficiency Specify:				To: From: To: From:	YYYY MM DD			
_	Dose: Name: Dose:		Specify: Inefficiency Specify: Inefficiency				To: From: To: From:	YYYY MM DD YYYY MM DD			
	Dose: Name: Dose: Name: Dose: PRESCRIPTION RENEWAL		Specify: Inefficiency Specify: Inefficiency Specify:				To: From: To: From:	YYYY MM DD YYYY MM DD			
F	Dose: Name: Dose: Name: Dose: PRESCRIPTION RENEWAL Refractory neuropathic pain and refract	ory pain in patient w	Specify: Inefficiency Specify: Inefficiency Specify:				To: From: To: From:	YYYY MM DD YYYY MM DD			
F	Dose: Name: Dose: Name: Dose: PRESCRIPTION RENEWAL Refractory neuropathic pain and refract Please describe the improvement in sym	ory pain in patient w	Specify: Inefficiency Specify: Inefficiency Specify: with advanced cancer: Dwing treatment:	Intoler	rance Contra	indication	To: From: To: From: To:	YYYY MM DD YYYYY MM DD YYYYY MM DD			
F	Dose: Name: Dose: Name: Dose: PRESCRIPTION RENEWAL Refractory neuropathic pain and refract Please describe the improvement in sym Has the patient started treatment with a	ory pain in patient w ptoms observed follonew analgesic or inc	Specify: Inefficiency Specify: Inefficiency Specify: with advanced cancer: Dwing treatment: creased the dosage of a	Intoler Intoler	rance Contra	indication	To: From: To: From: To:	YYYY MM DD YYYYY MM DD YYYYY MM DD			
F	Dose: Name: Dose: Name: Dose: PRESCRIPTION RENEWAL Refractory neuropathic pain and refract Please describe the improvement in sym Has the patient started treatment with a	ory pain in patient w ptoms observed follonew analgesic or inc	Specify: Inefficiency Specify: Inefficiency Specify: with advanced cancer: Dwing treatment:	Intoler Intoler	rance Contra	indication	To: From: To: From: To:	YYYY MM DD YYYY MM DD YYYYY MM DD			
i i	Dose: Name: Dose: Name: Dose: PRESCRIPTION RENEWAL Refractory neuropathic pain and refract Please describe the improvement in sym Has the patient started treatment with a	ory pain in patient w ptoms observed follonew analgesic or income	Specify: Inefficiency Specify: Inefficiency Specify: with advanced cancer: bying treatment: creased the dosage of a	Intoler Intoler	rance Contra	indication	To: From: To: From: To:	YYYY MM DD YYYY MM DD YYYYY MM DD			
F	Name: Dose: Name: Dose: PRESCRIPTION RENEWAL Refractory neuropathic pain and refract Please describe the improvement in sym Has the patient started treatment with a Yes No Please explain:	ory pain in patient w ptoms observed follonew analgesic or inco	Specify: Inefficiency Specify: Inefficiency Specify: With advanced cancer: Description treatment: Description of a series	Intoler Intoler	rance Contra	indication	To: From: To: From: To:	YYYY MM DD YYYY MM DD YYYYY MM DD			
! ! !	Name: Dose: Name: Dose: PRESCRIPTION RENEWAL Refractory neuropathic pain and refract Please describe the improvement in sym Has the patient started treatment with a Yes No Please explain: Refractory spasticity associated with mu	ory pain in patient w ptoms observed follonew analgesic or incontrol	Specify: Inefficiency Specify: Inefficiency Specify: With advanced cancer: Dowing treatment: Greased the dosage of a	Intoler nalgesic thera	rance Contra	indication	To: From: To: From: To:	YYYY MM DD YYYY MM DD YYYY MM DD YYYYY MM DD			
i F i F	Name: Dose: Name: Dose: PRESCRIPTION RENEWAL Refractory neuropathic pain and refract Please describe the improvement in sym Has the patient started treatment with a Yes No Please explain: Refractory spasticity associated with mu Please describe the improvement in sym Has the patient initiated a new treatmen	ory pain in patient w ptoms observed follonew analgesic or incontrol of the control of the contr	Specify: Inefficiency Specify: Inefficiency Specify: With advanced cancer: Dowing treatment: Greased the dosage of a	Intoler nalgesic thera	rance Contra	indication	To: From: To: From: To:	YYYY MM DD YYYY MM DD YYYY MM DD YYYYY MM DD			

D INSTRUCTIONS - HOW TO COMPLETE AND RETURN THIS FORM

- 1. Complete sections A and B.
- 2. Ask your physician to complete section C. The member is responsible for assuming any costs incurred to complete this form or to obtain additional information.
- 3. To obtain a reimbursement once the drug has been approved, please use your payment card at the pharmacy or submit your original receipts by mail. Eligible drugs must be dispensed by a pharmacist or a physician, if there is no pharmacist.

4. Send form: by fax : Desjardins Insurance by mail : Desjardins Insurance

Group Insurance, Health Claims,
418-838-2134 or 1-877-838-2134 (toll-free)
Group Insurance, Health Claims
C. P. 3950, Lévis (Québec) G6V 8C6

Under its prior authorization program, Desjardins Insurance authorizes the reimbursement of certain drugs that meet criteria that are based, in particular, on clinical practice guidelines and recommendations issued by health technology assessment organizations. The drug will be eligible for reimbursement if it meets the insurer's criteria, if it's not administered in a hospital and if it's not eligible under a government program. If the information on your form is complete, your request will normally be processed within 5 business days.

When the request form is received, it will be assessed in the strictest confidence. In some situations, additional diagnostic or clinical information may be required.

If the treatment continues beyond the authorized period, you will be asked to submit a new request form and provide information that justifies the extension of treatment. If you have a payment card, your pharmacist will be advised that the authorization period is coming to an end. The insurance must be in force and the patient still covered on the date expenses are incurred. This prior authorization is subject to change if, at the time expenses are incurred, the contract has been modified.

When Desjardins Insurance declines a prior authorization request, it is because we need to uphold conditions set out in the contract. It does not mean we are questioning the physician's opinion. If you have any questions, please contact our Customer Contact Centre at the number indicated on page 1 of this form.